The safety of rosiglitazone in the treatment of Type 2 diabetes

Expert Opinion on Drug Safety

Volumn 7, Issue 5, 2008, Pages 579-585

  Singh, Sonal ^a   Loke, Yoon K ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Cardiovascular adverse effects; Fractures; Heart failure; Myocardial infarction; Rosiglitazone; Safety

Indexed keywords

BIGUANIDE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; ARM FRACTURE; BLOOD TOXICITY; BONE DISEASE; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC DIET; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG SAFETY; EDEMA; EVIDENCE BASED MEDICINE; FLUID RETENTION; FRACTURE; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOCRIT; HIP FRACTURE; HUMAN; INSULIN SENSITIVITY; KINESIOTHERAPY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RETINA MACULA EDEMA; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; VISUAL IMPAIRMENT; WEIGHT GAIN; WRIST FRACTURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GLUCOSE BLOOD LEVEL; RISK FACTOR;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; FRACTURES, BONE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 54449086845     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.5.579     Document Type: Review

References (44)

1. Patel-H. Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991 - 2004. J Public Health 207;29(1):48-52
2. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007;30:2148-53
3. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;56:2457-71
5. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
6. Lefebvre AM, Peinado-Ousurbe J, Leitersdorf I, et al. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol 1997;17(9):1756-64
7. Hallakou S, Foufelle F, Doaré L, et al. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation. Diabetologia 1998;41(8):963-8
8. Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure (Greenwich). J Clin Hypertens 2006;8(1):19-28
9. Qayyum R, Adomaityte J. Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels. Am J Cardiol 2006;97(5):655-8
10. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104
11. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296(21):2572-81
12. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement flora the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31(1):173-5
13. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;18(3):CD006063
14. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;18(4):CD006060
15. European Agency for the Evaluation of Medicinal Products (EMEA). EPARS for authorized medicinal products for human use: Avandia. London, England, 2007. Available from: http://www.emea.europa.eu/humandocs/ Humans/EPAR/avandia/avandia.htm [Last accessed 10 July 2008]
16. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27(1):256-63
17. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-36
18. Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008;29(1):12-20
19. GlaxoSmithKline. GlaxoSmithKline clinical trial register: study no. ZM2005/00181/01, Avandia Cardiovascular Event Modeling Project, and study no. HM2006/00497/00/WEUSRTP866, Coronary Heart Disease Outcomes in Patients Receiving Antidiabetic Agents. Available from: http://ctr.gsk.co.uk/Summary/Rosiglitazone/III_CVmodeling.pdf [Last accessed 10 July 2008]
20. US Food and Drug Administration. FDA briefing document. Division of Metabolism and Endocrine Products and Office of Surveillance and Epidemiology. Joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee 30 July 2007. US Food and Drug Administration, 2007. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/ 2007-4308b1-02-fda-backgrounder.pdf [Last accessed 10 July 2008]
21. Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634-43
22. Sapunar J. Presentation title: Effect of baseline sample characteristics, comparator drug, co-interventions and rosiglitazone doses on the risk of myocardial infarction: multivariable lineal regression analysis. Abstract OC3.9 May 5 at the 10th European Congress of Endocrinology (ECE). Berlin. Available from: http://www.pslgroup.com/ news/content.nsf/medicalnews/ 852571020057CCF685257443005F1622?OpenDocument&id=&count=10 [Last accessed 10 July 2008]
23. US Food and Drug Administration. Information for healthcare professionals. Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl). US Food and Drug Administration, 14 August 2007. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/ rosiglitazone200707HCP.htm#2007_7 [Last accessed 10 July 2008]
24. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168(8):820-5
25. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-{gamma} agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;92:1305-10
26. Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;92(9):3523-30
27. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007;13(12):1496-503
28. Lazarenko OP, Rzonca SO, Hogue WR, et al. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007;148(6):2669-80
29. Takeda Pharmaceuticals. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HOI) tablets for Type 2 diabetes mellitus. Available from: http://www.fda.gov/medwaTCH/safety/2007/Actosmar0807.pdf [Last accessed 10 July 2008]
30. Berria R, Glass L, Mahankali A, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus. Clin Pharmacol Ther 2007;82(3):275-81
31. Avandia. Rosiglitazone maleate GlaxoSmithKline. Research Triangle Park, NC 27709 ©2008, GlaxoSmithKline February 2008. Available from: http://www.fda.gov/cder/foi/label/2008/021071s0321bl.pdf [Last accessed 10 July 2008]
32. Shvidel L, Arcavi L, Sigler E. Symptomatic anemia induced by rosiglitazone. Eur J Intern Med 2007;18(4):348
33. Slama G, Eschwège E, Bernard MH, et al.; pour le groupe des investigators de l'étude Avantage. One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: The Avantage Study. Ann Endocrinol (Paris) 2008;69(1):36-46
34. Thomas CM. Anemia in diabetes: marker or mediator of microvascular disease? Nat Clin Pract Nephrol 2007;3:20-30
35. Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina 2006;26(5):562-570
36. Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med 2007;5:17
37. Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 2008;31(7):1455-60
38. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59
39. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
40. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of rnacrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
41. Deeg MA, Buse JB, Goldberg RB, et al. On behalf of the GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007;30:2458-64
42. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28(7):1547-54
43. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99
44. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497